OS Therapies (OSTX) EBITDA (2023 - 2026)
OS Therapies' (OSTX) quarterly EBITDA came in at -$10.2 million in Q1 2026, down 103.38% YoY from $300.9 million in Q1 2025, and up 15.18% on a QoQ basis from -$12.0 million in Q4 2025.
OS Therapies (OSTX) EBITDA (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of EBITDA data on file, last reported at -$10.2 million in Q1 2026.
- Quarterly EBITDA fell 103.38% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.9 million (down 202.9% YoY) and the FY2025 annual result came in at -$28.7 million, down 321.28% from the prior year.
- EBITDA grew to -$10.2 million in Q1 2026, from -$12.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$622208.0 in Q3 2023 to a low of -$12.0 million in Q4 2025.
- A 4-year average of -$3.8 million and a median of -$2.4 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA jumped 48.54% — and 2025, when it sank 693.28%.
- Tracing OSTX's EBITDA over 4 years: stood at -$1.2 million in 2023, then tumbled by 156.38% to -$3.0 million in 2024, then slumped by 304.12% to -$12.0 million in 2025, then climbed by 15.18% to -$10.2 million in 2026.
- The last three EBITDA figures came in at -$10.2 million (Q1 2026), -$12.0 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | OS Therapies | 19.56 Mn | 19.56 Mn | - | -8.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.17 Mn |
| Dec 31, 2025 | -11.99 Mn |
| Sep 30, 2025 | -6.88 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -2.97 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -779,800.00 |
| Mar 31, 2024 | -630,232.00 |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -622,208.00 |
| Jun 30, 2023 | -1.52 Mn |
| Mar 31, 2023 | -1.05 Mn |